An experienced pharmaceuticals executive, Bruce Eaton is currently the president and CEO of i2 Pharmaceuticals Inc. Most recently, he served as the chief operating officer of SomaLogic. As an officer with the proteomics technology company, he managed all business development activities, as well as the licensing of IVD diagnostics products and copromotion of life science array product offerings. In addition to leading the company’s fee-for-service proteomics business, Bruce Eaton hired a number of sales and marketing professionals and established performance metrics to assess their efficacy. As a result of his efforts, the SomaLogic team was able to significantly increase its booked revenue by more than tenfold in the first year.
Bruce Eaton spent the early years of his career as the vice president of chemistry at NexStar Pharmaceuticals, where he was responsible for all chemistry operations at the company. He oversaw the synthesis and analytical chemistry groups at NexStar and led efforts in areas such as aptamer synthesis and new chemistry methods for the assemble of small molecule drug candidates. He was also a Co-Founder of Invenux a private technology platform company involved in drug discovery and small molecule libraries. As president, he patented new anti-MRSA compounds and acquired considerable intellectual property from Gilead to enable the company freedom to operate.
Bruce Eaton is a member of the American Association for the Advancement of Science and the American Chemical Society. He has been awarded 35 patents in the United States and more than 80 worldwide, primarily in the areas of chemistry, biotechnology, and medicinal chemistry. Over the course of his career, he has delivered more than 200 lectures, primarily in the United States and Europe.
Characteristics of an RNA Diels-Alderase active site